Citi reiterates sell rating on Moderna with $80 price target

Investing.com’s stocks of the week

Investing.com -- Cybersecurity names gained ground on a global software alert while Meta declined and a fresh escalation in the Middle East pushed crude to highs.

Here are Investing.coms stocks of the week:

Cybersecurity names were among the week's strong performers after an emergency security update for PHP, the programming language used by roughly 70% of websites worldwide, triggered a global alert. 

Two critical vulnerabilities disclosed this week could allow hackers to take remote control of affected servers.

The incident highlights a growing challenge,... More

Moderna shares continue to fall after early cancer vaccine data leak

Moderna Inc. shares dropped 2.3% in morning trading on Friday, adding to sharp losses from the previous session after clinical trial results for its personalized melanoma vaccine were published early by a medical news website on Thursday.

The Phase 3 data for intismeran autogene, developed with Merck & Co. (NYSE: MRK), was... More

Citi reiterates Sell rating on Moderna with $80 price target

Citi analyst Geoff Meacham reiterated a Sell rating and $80.00 price target on Moderna (NASDAQ: MRNA).

Meacham outlined ten reasons why positive melanoma trial data from the INTerpath-001 study do not address his concerns about the company's valuation. He noted that one successful study in... More

Moderna (MRNA) call put ratio 1 call to 1.4 puts amid wide share price movement

Moderna (NASDAQ: MRNA) 30-day option implied volatility is at 92; compared to its 52-week range of 57 to 138. Call put ratio 1 call to 1.4 puts amid wide share price movement.

RBC Capital Reiterates Sector Perform Rating on Merck (MRK)

RBC Capital analyst Trung Huynh reiterated a Sector Perform rating and $145.00 price target on Merck (NYSE: MRK).

The analyst comments "Our View: The INTerpath-001 data is clinically meaningful and likely approvable, offering patients an important new treatment option in high-risk melanoma. An RFS hazard ratio of... More

Citi keeps Sell rating on Moderna after melanoma trial data, PT $80

Citi analyst Geoff Meacham reiterated a Sell rating and $80.00 price target on Moderna (NASDAQ: MRNA) after phase 3 INTerpath-001 trial data showed the company's intismeran combined with pembrolizumab reduced the risk of recurrence or death by 42% compared to pembrolizumab alone in adjuvant melanoma, with a... More